Depomed (DEPO) Misses Q4 EPS by 13c

Depomed (NASDAQ: DEPO) reported Q4 EPS of $0.16, $0.13 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $111.2 million versus the consensus estimate of $110.24 million.

Non-GAAP adjusted earnings includes a reduction of $10 million, or $0.13 cents per share related to the tax treatment of the cebranopadol transaction.

For earnings history and earnings-related data on Depomed (DEPO) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04
• Star Equity to acquire Harte Hanks for $5 per share in cash and stock